Multiple Myeloma
Conditions
Interventions
investigational material(s)
Generic name etc : LY2127399
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational materia
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: * Have relapsed or refractory MM treated with at least 1 prior regimen. * Have measurable disease as defined by one or more of the following -serum M-protein concentration greater than or equal to 1 g/dL (10 g/L) -urine monoclonal light chain concentration greater than or equal to 200 mg/24 hours as determined by urine protein electrophoresis -involved serum free light chain (SFLC) concentration greater than or equal to 10 mg/dL (100 mg/L)and an abnormal SFLC ratio * Have adequate organ function (hematopoietic function, liver function, renal function). * Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of less than or equal to 2.
Exclusion criteria
Exclusion criteria: * Have one or more serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study. * Have known positive test results for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. * Have greater than or equal to Grade 2 peripheral neuropathy or any grade with pain as assessed using the Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v 4.03). * Have previously received an allogenic hematopoietic stem cell transplant. * Have a corrected QT (QTc) interval >470 msec on their baseline electrocardiogram (ECG).
Outcome results
None listed